Access comprehensive financial analyses and make smarter investments - get the Manual of Investments on Amazon!

CYH

Community Health Systems to Sell Crestwood Medical Center for $450 Million

Community Health Systems, Inc. (NYSE: CYH) has announced the definitive agreement to sell the 180-bed Crestwood Medical Center in Huntsville, Alabama, and its associated outpatient centers and practices for $450 million. This transaction is among the additional potential divestitures discussed on the Company's third-quarter 2025 earnings call and in subsequent public appearances.

As of now, the transaction is expected to close in the second quarter of 2026, subject to closing conditions. Leerink Partners is acting as the exclusive financial advisor to the Company for the transaction.

Community Health Systems, Inc. is one of the nation’s largest healthcare companies. The Company’s affiliates operate more than 1,000 sites of care, including physician practices, urgent care centers, freestanding emergency departments, occupational medicine clinics, imaging centers, cancer centers, and ambulatory surgery centers. The Company’s headquarters are located in Franklin, Tennessee.

The Company’s subsidiaries own or lease 69 affiliated hospitals with more than 10,000 beds. Shares in Community Health Systems, Inc. are traded on the New York Stock Exchange under the symbol “CYH.” The market has reacted to these announcements by moving the company's shares -4.19% to a price of $3.20. If you want to know more, read the company's complete 8-K report here.

The above analysis is intended for educational purposes only and was performed on the basis of publicly available data. It is not to be construed as a recommendation to buy or sell any security. Any buy, sell, or other recommendations mentioned in the article are direct quotations of consensus recommendations from the analysts covering the stock, and do not represent the opinions of Market Inference or its writers. Past performance, accounting data, and inferences about market position and corporate valuation are not reliable indicators of future price movements. Market Inference does not provide financial advice. Investors should conduct their own review and analysis of any company of interest before making an investment decision.

IN FOCUS